Eltrombopag

Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].

Product Specifications

CAS Number

[496775-61-2]

Product Name Alternative

SB-497115

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bacterial; Thrombopoietin Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Eltrombopag.html

Purity

99.94

Solubility

DMSO : 8.33 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(C2=CC=CC(N/N=C3C(C)=NN(C4=CC=C(C)C(C)=C4)C/3=O)=C2O)=CC=C1)O

Molecular Formula

C25H22N4O4

Molecular Weight

442.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27 (2) :424-30.|[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33 (1) :85-93.|[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel) . 2021 Nov 9;10 (11) :1372.|[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47 (5) :1696-702.